{"name":"Clovis Oncology, Inc.","slug":"clovis-oncology-inc","ticker":"","exchange":"","domain":"clovisoncology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":78000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-264524000,"cash":143428000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CO-1.01","genericName":"CO-1.01","slug":"co-1-01","indication":"Ovarian cancer (BRCA-mutated or homologous recombination deficient)","status":"phase_2"},{"name":"MPDL3280A","genericName":"MPDL3280A","slug":"mpdl3280a","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"CO-1.01","genericName":"CO-1.01","slug":"co-1-01","phase":"phase_2","mechanism":"CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death.","indications":["Ovarian cancer (BRCA-mutated or homologous recombination deficient)"],"catalyst":""},{"name":"MPDL3280A","genericName":"MPDL3280A","slug":"mpdl3280a","phase":"phase_3","mechanism":"MPDL3280A is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7-1, thereby releasing the brakes on anti-tumor immune responses.","indications":["Non-small cell lung cancer","Urothelial carcinoma","Gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"GlobeNewswire","summary":"Ovarian Cancer Drugs Market Outlook Report 2026-2030 - GlobeNewswire","headline":"Ovarian Cancer Drugs Market Outlook Report 2026-2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOYnF5MGxrTl9KZ0RkbGxKR2xweUpfdlRHRVItYWtYX0RHM3Zobi1ZcUZTbzd1eGFrS3RuU2trQ1F1VE1ORS1Yc0dOdG1NZ0xQTlpSWThIUXZIZVd2ZmgwckRfa2F3NDU3Q1VwVTRSMi1DYURiWi12d0JfdkJtS1RValB1UDR6OUstbXJacks2WHJwZFJVUGhmbHZFYUdGUzY3RE5KbUQ0T2wtVnc1dHhXTGx3?oc=5","date":"2025-11-19","type":"pipeline","source":"Research Nester","summary":"Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Report 2035 - Research Nester","headline":"Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Report 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE9iVW5oR2RuUUFyMlk0VjViNG5vRFZDSjFZUzVFV29yV0xmOXIwclE5ZXg4UkpJaERRRUtqdUI1V1QtNEV0V2hJS0c1WXFBQm9xaVlzVVN0X3V1OXpGaDZJOUtHMm9nMERwZThkZDNXaXRfb0pDSXc?oc=5","date":"2025-06-23","type":"regulatory","source":"Future Market Insights","summary":"Prostate Cancer Market Size & Demand Insights 2025 to 2035 - Future Market Insights","headline":"Prostate Cancer Market Size & Demand Insights 2025 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5EY1VkWE1EODd3cFVWVFQ0STA2aEtqNEJRbTVaZW1qdTJjVUlUZjY0ZV9tV1pZZDhjaWVJTktFaDNydS1nbjctLTlzWDNkYkZyQTJ2YmpGMXJ3bC1nTlIteUNab2JZVFo3QmV2bVhRdVI3aGM?oc=5","date":"2024-09-26","type":"pipeline","source":"Taylor & Francis Online","summary":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online","headline":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUFBHdkRIZ0puTkFoR0R4dzY1QzhQWVNZYUNpNHVudVRMbHI1UHdUd3NGdUVDVDM3OWJya2U0SXZjQ0xEcGYxZDFHUnpHSEkzZnBrWmJVMGhkbUlvQ1FCVnVGU2phZjU2ZW16RWdGREQ3TWNVZndCMm41eHNaT21md0dpSEhfVk9WcmtRMUt3?oc=5","date":"2023-08-21","type":"pipeline","source":"Frontiers","summary":"Overcoming the challenges of drug development in platinum-resistant ovarian cancer - Frontiers","headline":"Overcoming the challenges of drug development in platinum-resistant ovarian cancer","sentiment":"neutral"},{"date":"2023-07-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-06-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-06-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-05-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-05-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPWnRsNm1ydlFHRzM0MGxnTnRiamRZSVNMNGdsTEV2MVU0SFJ2TWpDUVdGcndkOERIeWpKWEIyc0xVZkxTTWMtUVZqV19GN0JYbmhzdTVPOXVVeHU1ZWxJRWJxWXR0RWVObHBiNFNkLUIwZTVfRjFWNGVnamJvdmQxekppTXRCV0k1SnpsVGZ6WUNrMkprTndBZGZzdWU1bzFsdVRTZnFPTUhzb1UzejQwLURyOHdWNE1BR1B2ZWhRamdpSUMwS2hhRUFILUdJcXRzMHhDaTdOOTRZQlVHeGdTaFNIQW5yZFlhQzljbDJoTHVhclRxVTh6cXVibTh5UXpwSUQ4MkRUc0k4OS1LTU1YRUx3?oc=5","date":"2023-04-30","type":"pipeline","source":"marketscreener.com","summary":"Zr pharma& GmbH completed the acquisition of certain assets and rights associated with Rubraca from Clovis Oncology, Inc. (OTCPK:CLVS.Q). - marketscreener.com","headline":"Zr pharma& GmbH completed the acquisition of certain assets and rights associated with Rubraca from Clovis Oncology, Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOcnRCSm95Sll1Z0p6bkVnNjZCZE5tLXd0S1R1VUlzbFNwbVZUTVZSTzBROGJkTlZCSEtSREJVWHhsVDJGSmdRYlRab1BoRUpKelU1X0ZycmpabmlUUVFnSDZNdjFmSnBUWlM5V0luNGJSUGRyWmI0dUhxU0VTbVFyd2hReXJUUUNNZ2lxc2tOMHk0Wm0yTFE1clhxcmljNldUSGtvVkpwVEpNS050eG1pcVZyZzFDdw?oc=5","date":"2023-04-24","type":"deal","source":"Fierce Biotech","summary":"Novartis pens $425M biobucks deal with German biotech, scooping up more radiopharmaceutical tech - Fierce Biotech","headline":"Novartis pens $425M biobucks deal with German biotech, scooping up more radiopharmaceutical tech","sentiment":"neutral"},{"date":"2023-04-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPWWhTWUNwM1NrSE8tZ0NKTXBIbVFDRTlQZDlSaTRpZGI0eGY4aldmLWI1LW1SbEFQdnFIZWpEaDJCXy1rRjVjX2NaWWR5M3JUVkI3XzR6Q3VNT2hHZTBua1NIMTNmV3A4X3ZueHpfVWdPU0RScUF6UGg3VWxLbVVRU2dXUURWVmQ3SFZxWVNPZkQzSFJhLWlkQWtnTUV3clk?oc=5","date":"2023-04-07","type":"regulatory","source":"Fierce Pharma","summary":"Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus - Fierce Pharma","headline":"Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNblRWblBJSjBXVmlLZTlKc0dVY01vWkxIT3hNMFhrc3R3d2JiYi15YTlJTVZLa1luS1FKV0JkNXFSVUtzMWNVR2FXQ3huYmF4VXJHbmRZRFRCYXo2TTRfbjFkS0cwdXpyOGw0bnN1Y3RYSnhhR1pvM3hVcmNFZG5wUHFtdTNuUjRGbnhkMlJCbnVXQQ?oc=5","date":"2023-04-07","type":"deal","source":"BioPharma Dive","summary":"Navigating bankruptcy, Clovis reaches deal to sell cancer drug Rubraca - BioPharma Dive","headline":"Navigating bankruptcy, Clovis reaches deal to sell cancer drug Rubraca","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":78000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":78000,"period":"2016-12-31"},{"value":0,"period":"2016-09-30"},{"value":0,"period":"2016-06-30"},{"value":0,"period":"2016-03-31"},{"value":0,"period":"2015-12-31"},{"value":0,"period":"2015-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-264524000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":143428000,"cashHistory":[],"totalAssets":472833000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}